New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
08:08 EDTCPRXCatalyst Pharmaceutical provides update on RND pipeline
Catalyst Pharmaceutical Partners, provided an update on its research and development pipeline. In October 2012, Catalyst acquired the North American rights to Firdapse, a proprietary form of amifampridine phosphate from BioMarin Pharmaceutical. Firdapse was approved in December 2009 by the European Medicines Agency for the treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS, a rare and sometimes fatal autoimmune disease characterized by muscle weakness. Firdapse has been granted orphan drug designation by the FDA for the treatment of LEMS, making the product eligible to obtain seven-year marketing exclusivity, if Catalyst is the first pharmaceutical company to obtain approval of an NDA for its formulation of amifampridine. Assuming positive results are obtained from the trial, Catalyst hopes to file an NDA for Firdapse in 1Q15, to obtain approval from the FDA of such NDA by the end of 2015, and to commercially launch this product sometime in the first half of 2016.Catalyst believes Firdapse can achieve peak annual revenues from sales in the U.S. of approximately $100M. On August 27, 2009, Catalyst entered into a license agreement with Northwestern University (Northwestern), under which it acquired worldwide rights to commercialize new GABA aminotransferase inhibitors and derivatives of vigabatrin which were discovered and patented by Northwestern. In October 2011, a pre-IND meeting was conducted with the FDA, during which preclinical and clinical requirements were defined that would allow Catalyst to complete a development program through Phase II of CPP-115 for the treatment of infantile spasms.
News For CPRX From The Last 14 Days
Check below for free stories on CPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:02 EDTCPRXCatalyst Pharmaceutical, BioMarin in amended license agreement
Catalyst Pharmaceutical (CPRX) disclosed in a regulatory filing that on April 15, effective as of April 8, the company and BioMarin Pharmaceutical (BMRN) entered into Amendment No. 1 to License Agreement, amending in certain respects the License Agreement, dated October 26, 2012, between the company and BioMarin. The company intends to submit a FOIA Confidential Treatment Request to the SEC pursuant to Rule 24b-2 under the SEC Act of 1934, as amended, requesting that it be permitted to redact certain portions of the Amendment. The omitted material will be included in the request for confidential treatment.
April 14, 2014
10:02 EDTCPRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:14 EDTCPRXCatalyst Pharmaceutical initiated with an Overweight at Piper Jaffray
Target $4.
April 3, 2014
09:05 EDTCPRXCatalyst Pharmaceutical 11.3M share Spot Secondary priced at $2.21
Piper Jaffray acted as sole book running manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use